2022-01-31T12:10:06-06:00 2021-03-31 EISNER ADVISORY GROUP LLC 733 THIRD AVENUE NEW YORK NY 100172703 990EZ 2020-04-01 833947490 ROIVANT SOCIAL VENTURES INC % RACHEL RUBIN ROIV 9146439551 151 WEST 42ND STREET 15TH FLOOR NEW YORK NY 10036 LINDSAY ANDROSKI PRESIDENT AND CEO 9146439551 2021-07-09 true LINDSAY ANDROSKI 999009999 CANDICE METH P01306891 2129498700 2020 2022-09-23 18:48:47Z X X WWW.ROIVANTSV.ORG X X 23041 X 23041 0 0 0 0 0 0 23041 0 7878 914 8792 14249 -14006 243 X 243 0 0 0 0 0 243 14006 0 -14006 243 X Our mission is to improve equity in health care access and outcomes across geographies, socioeconomics, and demographics on a not-for-profit, charitable basis. We use innovations in science and technology to challenge and advance the norms of biopharma and health care delivery. Our work is across two strategies: (i) investments and incubation leadership to early-stage innovative health access, manufacturing, and drug development organizations with no or low-cost "patient" capital and resources; (ii) charitable partnerships and educational initiatives across industry, patient advocacy, and investors accelerating development of new medicines and enhancing diversity in scientific leadership. THE ORGANIZATION HAS THE FOLLOWING INITIATIVES FOR THE FISCAL-YEAR ENDING MARCH 31, 2021: (I) Founding member of Global Gene Therapy Initiative (GGTI), a group of diverse stakeholders including charitable Organizations, academia, industry, and government whose Mission is to get access for cell and gene therapies to people in low- and middle-income countries (LMIC), bridging The gap towards health equity. GGTI WORKED TOWARDS PUBISHING ITs 1st Working Group Report WHICH IS EXPECTED TO highlight the Gaps in gene and cell therapies;(II) Initiation of a collaboration with Other charitable organizations focused on better understanding chronic neurological conditions including Diagnostic and prognostic indicators and developing therapies to slow progression and find a cure. One goal of this Collaboration is to include LMIC in the development of medical devices and therapies that can benefit those Populations, such as digital diagnostic devices and other Cheaper ways to understand and treat th 0 0 0 ERIC VENKER DIRECTOR & CHAIR 0.2 0 0 0 RAKHI KUMAR DIRECTOR & TREASURER 0.2 0 0 0 MATTHEW GLINE DIRECTOR & SECRETARY 0.2 0 0 0 LINDSAY ANDROSKI DIRECTOR, PRESIDENT AND CEO 0.5 0 0 0 false false false false false 0 false false 0 0 0 false 0 0 false AR CA CT HI KY MI MN MS NM NY OH PA TN VA WA RACHEL RUBIN 151 WEST 42ND STREET 15TH FLOOR NEW YORK NY 10036 9146439551 false false false false false false false false false false false NONE 0 NONE 0 true X 0 0 0 0 23041 23041 0 0 0 0 0 0 23041 23041 21936 1105 0 0 0 23041 X PUBLIC CHARITY STATUS SCHEDULE A, PART II THE ROIVANT FOUNDATION (NOW KNOWN AS "ROIVANT SOCIAL VENTURES, INC.") APPLIED FOR RECOGNITION OF EXEMPTION UNDER SECTION 501(C)(3) IN JULY 2020. IN SEPTEMBER 2020, IT WAS DETERMINED TO BE EXEMPT UNDER SECTION 501(C)(3) AND CLASSIFIED AS A PUBLIC CHARITY UNDER SECTION 170(B)(1(A)(VI) EFFECTIVE NOVEMBER 21, 2018 (DATE OF INCORPORATION.) PRIOR TO OBTAINING EXEMPT STATUS AS A PUBLIC CHARITY, THE ORGANIZATION FILED FORM 990-PF FOR ITS MARCH 31, 2019 TAX YEAR END. SUBSEQUENT TO DETERMINATION DATE, IT FILES THE FORM 990. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED FORM 990-EZ, HEADER BOX B EFFECTIVE MAY 18, 2021, THE ORGANIZATION FILED AN AMENDMENT TO ITS BY-LAWS WITH THE STATE OF DELAWARE, THE ORGANIZATION'S STATE OF INCORPORATION, TO CHANGE THE ORGANIZATION'S NAME FROM ROIVANT FOUNDATION INC. TO ROIVANT SOCIAL VENTRUES, INC. THIS CHANGE OF NAME WAS REPORTED TO THE INTERNAL REVENUE SERVICE THROUGH CORRESPONDENCE IN JULY 2021. AS OF THE DATE OF THIS FILING, THE ORGANIZATION IS AWAITING acknowledgement FROM THE INTERNAL REVENUE SERVICE FOR THIS REQUESTED CHANGE. FORM 990EZ PART I LINE 16 Description:CONSULTING FEES Amount:795 FORM 990EZ PART I LINE 16 Description:FILING FEES Amount:110 FORM 990EZ PART I LINE 16 Description:BANK CHARGES Amount:9